Uncategorized

Intellia finds genetic suspect for liver safety signals with ATTR gene therapy

Intellia finds genetic suspect for liver safety signals with ATTR gene therapy

Published

on

In November 2025, one patient died after receiving Intellia Therapeutics’ investigational gene silencer for transthyretin amyloidosis.​ ​Read More

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending

Exit mobile version